Clinical Chemistry Case Studies: Applying Laboratory Data to Patient Care

Clinical chemistry case studies bridge the gap between isolated laboratory values and coherent patient management decisions. This article provides a structured approach to interpreting clinical chemistry results through case-based learning, with emphasis on analytical quality, biological variation, reference interval application, and the limitations of laboratory data. The content is designed for laboratory students, technicians, researchers, and diagnostic professionals who need to translate numerical results into clinically meaningful information. A self-assessment case study template is included to support structured interpretation practice.

At a Glance: Core Elements of Clinical Chemistry Case Interpretation

The Role of Case Studies in Laboratory Education

Case-based instruction has demonstrated measurable value in health professions education. Survey data from pharmacy students showed that 88 percent of second-year participants and 92 percent of third-year participants reported that case studies enhanced their learning and appreciation for medicinal chemistry content [9]. The same principle applies to clinical chemistry education. Working through realistic patient scenarios forces the learner to integrate analytical knowledge with pathophysiological reasoning instead of memorizing isolated facts.

The case study method also mirrors the actual workflow of clinical laboratories. When a result falls outside the reference interval, the laboratorian must consider analytical error, biological variation, preanalytical issues, and clinical context before releasing the result. Peer-reviewed case exercises published through programs such as Check Sample provide structured opportunities for laboratory professionals to develop these interpretive skills across clinical chemistry and related disciplines [12].

Core Principles of Laboratory Result Interpretation

Reference Intervals and Their Limitations

Reference intervals are the foundation of result interpretation, yet they carry inherent limitations. Population-based reference intervals may obscure important information related to individual biological variation [15]. For analytes with high individuality, a patient's serial results may remain within their personal homeostatic range even when they cross the population reference limit. Conversely, a result within the population interval may represent a significant change for that individual.

Pediatric reference intervals present additional complexity. A Canadian Laboratory Initiative on Pediatric Reference Intervals study established reference intervals for 27 routine chemistry analytes on the Roche cobas pro platform and found that age-specific partitions were required for 23 of 27 analytes [14]. Electrolytes such as sodium and chloride remained stable across all ages, while analytes influenced by growth, bone metabolism, liver function, and muscle mass demonstrated marked age and sex related variation [14]. Applying adult reference intervals to pediatric samples can therefore produce misleading interpretations.

Analytical Quality Specifications

Reliable interpretation depends on reliable measurement. The Milan consensus established three models for analytical performance specifications: based on biological variation, based on clinical outcome, and based on state of the art [22]. The biological variation model calculates allowable total error from within-subject and between-subject variation components. This approach links analytical quality directly to the clinical use of the test result.

Measurement uncertainty concepts have partially replaced the traditional total error model in some applications. The bias component remains controversial, with debate over whether bias should be included in uncertainty calculations or treated separately [22]. Laboratories must understand the performance specifications applied to their methods to judge whether observed changes in patient results reflect true physiological variation or analytical noise.

Biological Variation and Index of Individuality

The index of individuality compares within-subject variation to between-subject variation. When the index is below 0.6, population reference intervals have limited applicability for serial monitoring of that individual [15]. A study of 45 healthy adults sampled weekly for six weeks demonstrated high individuality for liver enzymes, albumin, creatinine, ferritin, thyroid hormones, and lipids [15]. This finding means that for these analytes, a patient's result may move outside the population reference interval while remaining within their personal homeostatic range.

Conversely, iron demonstrated an index of individuality above 1.4, supporting the validity of population-based intervals for this analyte [15]. Personalized reference intervals derived from biological variation estimates were generally narrower than population intervals, with 94.7 percent of reference interval index values below 1 [15]. For serial monitoring, understanding the individuality of each analyte helps determine whether a change is clinically significant.

Practical Workflow for Case-Based Interpretation

Step 1: Verify Analytical Validity

Before interpreting any result, confirm that the measurement is analytically valid. Check quality control data for the run, verify the result is within the analytical measuring range, and assess whether dilution or repeat testing is required. A model developed at the University Hospital of Padua demonstrated that not all tests require exact numerical values for patient management [16]. For 15 analytes requiring manual dilution beyond automated limits, the laboratory defined upper reporting limits beyond which exact values were not routinely required, with the exception of lactate dehydrogenase where oncologic follow-up necessitated precise reporting [16]. This approach eliminated most manual dilutions, reduced costs, and improved turnaround time [16].

Step 2: Assess Preanalytical Factors

Evaluate specimen quality and handling. Hemolysis, lipemia, and icterus can interfere with many chemistry methods. Specimen matrix selection is particularly important for biomarkers influenced by preanalytical variability [17]. For example, circulating biomarkers of neutrophil activation and NETosis, including myeloperoxidase, neutrophil elastase, and citrullinated histone H3, require careful attention to specimen handling because these analytes are susceptible to ex vivo activation and degradation [17].

Step 3: Apply Appropriate Reference Intervals

Select reference intervals that match the patient's age, sex, and clinical context. For pediatric patients, use age and sex specific intervals instead of adult ranges [14]. For serial monitoring, consider whether the analyte has high individuality that would support personalized reference intervals [15].

Step 4: Integrate Clinical Context

Laboratory results must be interpreted within the clinical presentation. A single abnormal value rarely establishes a diagnosis. Consider the pretest probability of disease, the sensitivity and specificity of the test, and the presence of confounding conditions. For example, glycated albumin has gained attention as a complementary biomarker for dysglycemia when HbA1c interpretation is limited by altered erythrocyte survival, anemia, hemoglobin variants, or chronic kidney disease [18]. The choice of glycemic marker depends on the clinical scenario.

Step 5: Document and Communicate

Record the interpretation, including the reasoning process and any limitations. When results are ambiguous or conflicting, communicate directly with the requesting clinician. Clear documentation supports continuity of care and provides a basis for future comparison.

Case Study Template for Self-Assessment

The following template provides a structured framework for working through clinical chemistry cases. Use this format to document your interpretation process and identify gaps in your reasoning.

Patient Demographics and Clinical Presentation

Record age, sex, relevant medical history, current medications, and the reason for laboratory testing. Note any symptoms or physical findings that prompted the investigation.

Laboratory Results

List all available results with units and the reference intervals used. Flag results outside the reference interval and note the magnitude of deviation.

Analytical Assessment

Evaluate the quality of the measurements. Were quality control results acceptable? Were any results outside the analytical measuring range? Were there any preanalytical concerns such as hemolysis or delayed processing?

Reference Interval Evaluation

Confirm that the reference intervals applied are appropriate for the patient's age and sex. Consider whether the analyte has high individuality that would affect interpretation of serial results.

Clinical Correlation

Connect the laboratory findings to the clinical presentation. What conditions could explain the pattern of results? Are there alternative explanations, including analytical error or preanalytical issues?

Differential Diagnosis

List possible diagnoses based on the laboratory pattern and clinical context. Rank them by likelihood and identify additional tests that would help distinguish between them.

Recommended Actions

Specify the next steps, including additional laboratory testing, clinical consultation, or repeat testing at an appropriate interval.

Learning Points

Document what this case taught you about clinical chemistry interpretation. Note any errors in your initial reasoning and how you would approach similar cases in the future.

Common Failure Patterns in Case Interpretation

Overreliance on Population Reference Intervals

Applying population reference intervals without considering biological individuality can lead to false alarms or missed changes. For analytes with high individuality, serial results should be compared to the patient's own baseline instead of the population range [15].

Ignoring Analytical Limitations

Every method has limitations, including the analytical measuring range, interference susceptibility, and imprecision at various concentrations. Results near the limit of quantification or above the linearity range require special handling [16]. Cortisol immunoassays demonstrate the importance of method-specific performance, with one study showing that a Siemens immunoassay had a bias of 25.3 percent compared to LC-MS/MS, which improved to 4.9 percent with the Siemens CSI assay [19].

Misinterpreting Serial Changes

Without understanding biological variation, it is easy to overinterpret small changes between serial measurements. The reference change value, calculated from analytical and within-subject variation, provides a statistically valid threshold for significant change. Laboratories should calculate and apply reference change values for analytes used in monitoring.

Confusing Correlation with Causation

Laboratory abnormalities may be associated with a condition without being causative. For example, circulating NETosis biomarkers are associated with adverse clinicopathological features and poor survival in cancer patients, but current evidence remains exploratory because most studies are small and assays are heterogeneous [17]. Interpretation should acknowledge the strength and limitations of the evidence base.

Quality Control and Assurance in Case-Based Learning

Internal Quality Control

Regular analysis of quality control materials verifies that methods remain within acceptable performance specifications. Control results should be reviewed against Westgard rules or equivalent multi-rule procedures. The allowable total error for each analyte should be derived from biological variation data or clinical outcome studies [22].

External Quality Assessment

Participation in external quality assessment programs provides independent verification of method performance. Inter-laboratory comparability varies by assay and manufacturer. A national evaluation of cortisol immunoassays found acceptable comparability and inter-laboratory performance for Roche and Abbott assays, while a Beckman Coulter immunoassay showed high imprecision requiring improvement [19].

Method Validation

New methods require validation before implementation in clinical use. The U.S. Food and Drug Administration provides guidance for bioanalytical method validation that addresses accuracy, precision, selectivity, sensitivity, reproducibility, and stability [4]. The National Center for Advancing Translational Sciences Assay Guidance Manual provides additional technical guidance for assay development and validation [3].

Safety and Regulatory Context

Laboratory professionals must follow established biosafety practices when handling patient specimens. The World Health Organization Laboratory Biosafety Manual provides guidance on risk assessment, containment principles, and safe handling of biological materials [2]. The Laboratory Quality Management System Handbook addresses the organizational and operational requirements for quality in laboratory testing [1].

Case-based teaching materials should also address the regulatory context of laboratory testing. The Clinical Chemistry, Immunology and Laboratory Quality Control text provides comprehensive review content for board preparation and certification, covering the integration of quality control principles with clinical practice [27].

Artificial Intelligence and Laboratory Interpretation

The emergence of natural language processing tools has raised questions about their role in laboratory result interpretation. An assessment by the European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Artificial Intelligence tested ChatGPT on 10 simulated laboratory reports [20]. The tool recognized all laboratory tests and detected deviations from reference intervals, but interpretations were superficial, not always correct, and only sometimes coherent [20]. The magnitude of deviation from the reference interval seldom influenced interpretation, and the tool did not make meaningful suggestions regarding follow-up diagnostics [20].

This assessment concluded that current natural language processing tools are not specifically trained on medical or laboratory data and may only interpret laboratory reports on a test-by-test basis at best [20]. Laboratory professionals should understand both the potential and the limitations of these tools. Artificial intelligence may eventually support data-driven approaches to laboratory interpretation, but current systems require human oversight and clinical judgment.

Case Study 1: Abnormal Liver Chemistry in a Clinical Trial Participant

A 55 year old male participant in a late stage clinical trial presents with elevated liver enzymes on routine monitoring. Baseline laboratory results showed mildly elevated bilirubin and gamma-glutamyltransferase. Predictive models developed from 24 late stage clinical trials demonstrated that baseline data could predict which patients would develop liver chemistry signals during trials with average validation accuracy around 80 percent [25]. High bilirubin levels at baseline were associated with a high risk of developing biochemical Hy's law cases [25].

This case illustrates the importance of baseline assessment in interpreting subsequent laboratory changes. The laboratorian should compare current results to baseline values, evaluate the pattern of liver enzyme elevation, and consider whether the changes meet criteria for drug-induced liver injury. Baseline gamma-glutamyltransferase level appeared to have some predictive value but did not increase predictability beyond using established liver chemistry tests [25].

Case Study 2: Glycemic Monitoring in a Patient with Chronic Kidney Disease

A 62 year old female with chronic kidney disease requires assessment of glycemic control. HbA1c interpretation is limited by altered erythrocyte survival associated with her condition. Glycated albumin has gained attention as a complementary biomarker for dysglycemia in this setting [18]. The proposed GA-PATH framework focuses on population calibration, albumin-turnover safeguards, triage logic, harmonization, and health-equity analytics [18].

This case demonstrates the need to select laboratory tests based on the clinical context. The laboratorian should verify that the glycated albumin method is appropriately calibrated for the population and that albumin turnover is stable. Results should be interpreted with awareness of the limitations of the biomarker and the need for confirmatory testing.

Case Study 3: Cortisol Measurement During Dynamic Endocrine Testing

A patient undergoes dynamic testing for suspected adrenal disorders. Cortisol measurements are performed using an immunoassay, and the results are compared to established diagnostic criteria. Considerable variation between cortisol assays may prevent the interchangeability of dynamic test results and interpretation [19]. A national evaluation found that the original Siemens immunoassay showed poor agreement with LC-MS/MS with a bias of 25.3 percent, which improved substantially with the Siemens CSI assay to 4.9 percent [19].

This case highlights the importance of knowing the analytical performance of the specific assay used in the laboratory. Diagnostic criteria developed using one method may not be transferable to another method. The laboratorian should document the assay used and communicate any limitations to the requesting clinician.

Case Study 4: Seroprevalence Monitoring Using Residual Samples

A public health investigation aims to estimate SARS-CoV-2 seroprevalence in children. Residual blood samples from routine clinical chemistry testing are used for antibody testing [21]. In a repeated cross-sectional cohort study, 2,626 individual blood samples from pediatric patients were analyzed for anti-S and anti-N antibodies [21]. Seroprevalence increased over three time periods, and comparison with national surveillance data indicated a 3.93 to 5.66 fold increase in the number of unreported cases [21].

This case demonstrates the utility of residual samples for public health surveillance while highlighting the importance of ethical considerations and sample quality. The laboratorian must ensure that residual sample use complies with institutional policies and that testing does not compromise patient care.

Records and Documentation Requirements

Accurate documentation is essential for case-based learning and clinical practice. Records should include the patient identifier, specimen collection date and time, test results with units, reference intervals, quality control data, and any comments about analytical or preanalytical issues. For teaching cases, documentation should also include the interpretation process and learning points.

The Laboratory Quality Management System Handbook provides guidance on record keeping requirements for laboratory testing [1]. Records should be legible, permanent, and retrievable. Electronic records require appropriate access controls and backup procedures.

Limitations of Case-Based Learning

Case studies provide valuable learning opportunities but have inherent limitations. Each case represents a single patient encounter and may not reflect the full spectrum of presentations for a given condition. The Clinical Chemistry, Immunology and Laboratory Quality Control text emphasizes the importance of comprehensive review for board preparation, suggesting that case studies should supplement instead of replace systematic study [27].

Case-based learning also requires accurate and complete data. Incomplete clinical information can lead to incorrect interpretations. Learners should be encouraged to identify missing information and consider how it might affect their conclusions.

Professional Escalation Criteria

Laboratory professionals should escalate concerns when results are critical, unexpected, or inconsistent with the clinical picture. Specific situations requiring escalation include:

• Results that exceed critical limits and require immediate clinical notification
• Patterns suggestive of specimen mix-up or collection error
• Results inconsistent with previous values without a plausible explanation
• Quality control failures that may affect patient results
• Suspected interference or analytical error

When escalating, provide the relevant data, the reason for concern, and any recommended actions. Clear communication with clinical colleagues supports appropriate patient management.

Frequently Asked Questions

How do I determine if a change between serial results is clinically significant?

Calculate the reference change value using the analytical imprecision and within-subject biological variation for the analyte. If the difference between two results exceeds the reference change value, the change is statistically significant at the chosen probability level. For analytes with high individuality, compare results to the patient's own baseline instead of the population reference interval [15].

What is the index of individuality and why does it matter?

The index of individuality compares within-subject biological variation to between-subject variation. When the index is below 0.6, population reference intervals have limited applicability for interpreting individual results [15]. This means a patient's result may fall outside the population interval while remaining within their personal homeostatic range. For analytes with high individuality, serial monitoring and personalized reference intervals are more appropriate than population comparisons.

When should I use pediatric reference intervals instead of adult intervals?

Pediatric reference intervals should be used for all patients under 19 years of age. A study of 27 routine chemistry analytes found that age-specific partitions were required for 23 of 27 analytes [14]. Electrolytes such as sodium and chloride remained stable across all ages, but analytes influenced by growth, bone metabolism, liver function, and muscle mass demonstrated marked age and sex related variation [14].

How do I handle results above the analytical measuring range?

Results above the analytical measuring range require dilution and repeat analysis to obtain an exact value. However, not all tests require exact numerical values for patient management. Laboratories can define upper reporting limits beyond which exact values are not routinely required, based on clinical input and literature review [16]. Lactate dehydrogenase was identified as an analyte where precise reporting was necessary for oncologic follow-up [16].

What are the limitations of using artificial intelligence for laboratory result interpretation?

Current natural language processing tools are not specifically trained on medical or laboratory data. An assessment by the European Federation of Clinical Chemistry and Laboratory Medicine found that ChatGPT recognized laboratory tests and detected deviations from reference intervals, but interpretations were superficial and not always correct [20]. The tool did not make meaningful suggestions regarding follow-up diagnostics [20]. Human oversight and clinical judgment remain essential.

How do I select the appropriate glycemic marker for patients with chronic kidney disease?

HbA1c interpretation is limited by altered erythrocyte survival, anemia, hemoglobin variants, and chronic kidney disease. Glycated albumin has gained attention as a complementary biomarker in these settings [18]. Consider albumin turnover status and ensure the method is appropriately calibrated for the population. The choice of marker should be guided by the clinical scenario and the limitations of each test.

Why do cortisol results vary between different immunoassays?

Cortisol immunoassays demonstrate considerable variation between manufacturers. A national evaluation found that the original Siemens immunoassay had a bias of 25.3 percent compared to LC-MS/MS, which improved to 4.9 percent with the Siemens CSI assay [19]. Roche and Abbott assays showed good agreement with LC-MS/MS [19]. Diagnostic criteria developed using one method may not be transferable to another method.

How can residual samples be used for public health surveillance?

Residual blood samples from routine clinical chemistry testing can be used for seroprevalence monitoring when appropriately anonymized and approved. A pediatric study used residual samples to estimate SARS-CoV-2 seroprevalence and found a 3.93 to 5.66 fold increase in unreported cases compared to national surveillance data [21]. Ethical considerations, sample quality, and institutional policies must be addressed before using residual samples for research purposes.

Related Diagnostic Guides

• Laboratory Results Template: How to Present Data Clearly and Reproducibly
• Multiplex Real-Time RT-PCR for Differential Diagnosis of Canine Infectious Respiratory Disease Complex (CIRDC): Panel Design, Validation, and Clinical Utility
• Establishing Reference Intervals in Veterinary Clinical Chemistry
• No Template Control (NTC) in qPCR: Setup, Interpretation, and Troubleshooting
• qPCR Data Presentation: How to Report Results in Figures and Tables

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Antibody-Drug Conjugates-A Tutorial Review.. Molecules (Basel, Switzerland), 2021.
• Artificial intelligence in antibody-drug conjugate development.. Trends in pharmacological sciences, 2025.
• Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success.. Journal of medicinal chemistry, 2025.
• Case-based studies in teaching medicinal chemistry in PharmD curriculum: Perspectives of students, faculty, and pharmacists from academia.. Currents in pharmacy teaching & learning, 2018.
• The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education.. American journal of pharmaceutical education, 2018.
• Structural Simplification of Natural Products.. Chemical reviews, 2019.
• Check Sample Abstracts.. American journal of clinical pathology, 2009.
• Clinical Applications of Targeted Nanomaterials.. Pharmaceutics, 2025.
• Pediatric reference intervals for 27 routine chemistry analytes in healthy children and adolescents on the Roche cobas pro platform.. 2026.
• Personalized reference intervals for biochemical, hormonal, and coagulation tests: Comparison with population-based reference intervals.. 2026.
• A model to increase automation and support reliable interpretation of clinical chemistry tests.. 2026.
• Circulating NETosis biomarkers in oncology.. 2026.
• Glycated albumin beyond HbA1c: an equity-ready laboratory pathway for emergency diabetes and cardiorenal risk screening.. 2026.
• National comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methods.. 2026.
• Potentials and pitfalls of ChatGPT and natural-language artificial intelligence models for the understanding of laboratory medicine test results. An assessment by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group on Artificial Intelligence (WG-AI). Clinical Chemistry and Laboratory Medicine, 2023.
• Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2022.
• Analytical performance specifications in clinical chemistry: the holy grail?. 2017.
• Thiourea compounds as multifaceted bioactive agents in medicinal chemistry.. Bioorganic chemistry (Print), 2025.
• Drug-Induced Photosensitivity-From Light and Chemistry to Biological Reactions and Clinical Symptoms. Pharmaceuticals, 2021.
• Pretreatment data is highly predictive of liver chemistry signals in clinical trials. Drug Design, Development and Therapy, 2012.
• Manual of Veterinary Clinical Chemistry: A Case Study Approach. Manual of Veterinary Clinical Chemistry A Case Study Approach, 2010.
• Clinical Chemistry, Immunology and Laboratory Quality Control: A Comprehensive Review for Board Preparation, Certification and Clinical Practice. Clinical Chemistry Immunology and Laboratory Quality Control A Comprehensive Review for Board Preparation Certification and Clinical Practice, 2021.
• Harmonizing analytical chemistry and clinical epidemiology for human biomonitoring studies. A case-study of plastic product chemicals in urine. Chemosphere, 2020.
• Evaluation of computerized medicinal chemistry case study modules as tools to enhance student learning and clinical problem-solving skills. American Journal of Pharmaceutical Education, 1999.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.